newsfilter
← Latest News
GlobeNewswire·

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of VERVE-101 in November 2023